Evaluation of health-care utilization among adult patients with epilepsy in Germany

Epilepsy and Behavior

Volumn 23, Issue 4, 2012, Pages 451-457

  Strzelczyk, Adam ^a   Nickolay, Tanja ^a   Bauer, Sebastian ^a   Haag, Anja ^a   Knake, Susanne ^a   Oertel, Wolfgang H ^a   Reif, Philipp S ^a   Rosenow, Felix ^a   Reese, Jens P ^a   Dodel, Richard ^a   Hamer, Hajo M ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cost; Economic burden; Epilepsy; Indirect cost; Resource use; Retirement; Seizure; Work loss

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC STATE; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; QUESTIONNAIRE; RETIREMENT; SOCIAL STATUS; UNEMPLOYMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; COHORT STUDIES; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; GERMANY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; VIDEO RECORDING; YOUNG ADULT;

EID: 84859164216     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.01.021     Document Type: Article

References (52)

1. Forsgren L., Beghi E., Oun A., Sillanpaa M. The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 2005, 12:245-253.
2. van Hout B., Gagnon D., Souetre E., et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997, 38:1221-1226.
3. Haag A., Strzelczyk A., Bauer S., Kuhne S., Hamer H.M., Rosenow F. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients. Epilepsy Behav 2010, 19:618-622.
4. Dodel R.C., Pepperl S., Kohne-Volland R., et al. Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy. Med Klin (Munich) 1996, 91:479-485.
5. Hamer H.M., Spottke A., Aletsee C., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47:2165-2172.
6. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005, 12(Suppl 1):1-27.
7. Forsgren I., Beghi E., Ekman M. Cost of epilepsy in Europe. Eur J Neurol 2005, 12(Suppl 1):54-58.
8. Strzelczyk A., Reese J.P., Dodel R., Hamer H.M. Cost of epilepsy: a systematic review. Pharmacoeconomics 2008, 26:463-476.
9. Marinas A., Elices E., Gil-Nagel A., et al. Socio-occupational and employment profile of patients with epilepsy. Epilepsy Behav 2011, 21:223-227.
10. Helmers S.L., Duh M.S., Guerin A., et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav 2011, 22:370-375.
11. Helmers S.L., Paradis P.E., Manjunath R., et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 2011, 18:437-444.
12. Knake S., Rosenow F., Vescovi M., et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001, 42:714-718.
13. Fisher R.S., van Emde Boas W., Blume W., et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
14. Institute for Quality and Efficiency in Health Care. (IQWiG) - Technical Document on Cost Estimation - published online 09.10.2008, http://www.iqwig.de.
15. Schöffski O., v.d.Schulenburg J. Gesundheitsökonomische Evaluationen 2007, Springer, Berlin. 3. edition.
16. v.d.Schulenburg J.M., Greiner W., et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544.
17. Arbeitsgemeinschaft Pharmazeutische Industrie Bundesverband der Pharmazeutischen Industrie. Rote Liste. Aulendorf,: Editio Cantor [etc.] 2008, v.
18. Krauth C., Hessel F., Hansmeier T., Wasem J., Seitz R., Schweikert B. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005, 67:736-746.
19. Reese J.P., Winter Y., Balzer-Geldsetzer M., et al. Parkinson's disease: cost-of-illness in an outpatient cohort. Gesundheitswesen 2011, 73:22-29.
20. Spottke A.E., Reuter M., Machat O., et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005, 23:817-836.
21. Winter Y., Stamelou M., Cabanel N., et al. Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 2011, 258:1827-1834.
22. Kolominsky-Rabas P.L., Heuschmann P.U., Marschall D., et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006, 37:1179-1183.
23. Barber J.A., Thompson S.G. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000, 19:3219-3236.
24. Dodel I., Reese J.P., Muller N., et al. Cost of illness in patients with Gilles de la Tourette's syndrome. J Neurol 2010, 257:1055-1061.
25. Winter Y., Wolfram C., Schaeg M., et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol 2009, 256:954-963.
26. Begley C.E., Beghi E., Beran R.G., et al. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: Final report 1998-2001. Epilepsia 2002, 43:668-673.
27. Brunetti M., Pagano E., Garattini L. The economic cost of epilepsy: a review. Ital J Neurol Sci 1998, 19:116-119.
28. Annegers J.F., Beghi E., Begley C.E. Cost of epilepsy: contrast of methodologies in United States and European studies. Epilepsia 1999, 40(Suppl 8):14-18.
29. Beghi E., Garattini L., Ricci E., Cornago D., Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004, 45:171-178.
30. Tetto A., Manzoni P., Millul A., et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002, 48:207-216.
31. Sancho J., Pena P., Rufo M., Palacios G., Masramon X., Rejas J. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res 2008, 81:176-187.
32. Hong Z., Qu B., Wu X.T., Yang T.H., Zhang Q., Zhou D. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia 2009, 50:2192-2198.
33. Garcia-Contreras F., Constantino-Casas P., Castro-Rios A., et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res 2006, 37:376-383.
34. Tsiropoulos I., Gichangi A., Andersen M., Bjerrum L., Gaist D., Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006, 113:405-411.
35. Johannessen Landmark C., Fossmark H., Larsson P.G., Rytter E., Johannessen S.I. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 2011, 95:51-59.
36. De Zelicourt M., Buteau L., Fagnani F., Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000, 9:88-95.
37. Gilliam F., Kuzniecky R., Faught E., Black L., Carpenter G., Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997, 38:233-236.
38. Wirrell E.C. Epilepsy-related injuries. Epilepsia 2006, 47(Suppl 1):79-86.
39. Friedman D.E., Gilliam F.G. Seizure-related injuries are underreported in pharmacoresistant localization-related epilepsy. Epilepsia 2010, 51:43-47.
40. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F., Hauser W.A. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994, 35:1230-1243.
41. Cockerell O.C., Hart Y.M., Sander J.W., Shorvon S.D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994, 18:249-260.
42. Mak W., Fong J.K., Cheung R.T., Ho S.L. Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 1999, 8:456-464.
43. Murray M.I., Halpern M.T., Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996, 23:139-148.
44. Krishnan A., Sahariah S.U., Kapoor S.K. Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 2004, 45:289-291.
45. Thomas S.V., Sarma P.S., Alexander M., et al. Economic burden of epilepsy in India. Epilepsia 2001, 42:1052-1060.
46. Jennum P., Gyllenborg J., Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 2011, 52:949-956.
47. Thorbecke R., Specht U. Rehabilitation und Berufstätigkeit bei Menschen mit Epilepsie. TW Neurol Psychiatr 1993, 7:283-288.
48. Pfäfflin M., May T., Stefan H., Adelmeier U. Impact of epilepsy on daily living and employment of patients in primary care. Neurol Rehabil 2000, 6:140-148.
49. Smeets V.M., van Lierop B.A., Vanhoutvin J.P., Aldenkamp A.P., Nijhuis F.J. Epilepsy and employment: literature review. Epilepsy Behav 2007, 10:354-362.
50. Gustavsson A., Svensson M., Jacobi F., et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21:718-779.
51. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999, 33:39-55.
52. Koopmanschap M.A., Rutten F.F., van Ineveld B.M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.